A Validated Stability-indicating Liquid Chromatographic Method for Determination of Cabazitaxel-A Novel Microtubule Inhibitor
- *Corresponding Author:
- Mathrusri Annapurna Mukthinuthalapati
Department of Pharmaceutical Analysis & Quality Assurance
GITAM Institute of Pharmacy
GITAM University, Visakhapatnam, India
E-mail: [email protected]
Received Date: June 23, 2014; Accepted Date: July 28, 2014; Published Date: August 06, 2014
Citation: Mukthinuthalapati MA, Bukkapatnam V, Grandhi NS (2014) A Validated Stability-indicating Liquid Chromatographic Method for Determination of Cabazitaxel-A Novel Microtubule Inhibitor. J Bioequiv Availab 6: 134-138. doi: 10.4172/jbb.10000193
Copyright: © 2014 Mukthinuthalapati MA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cabazitaxel is used to treat advanced prostate cancer. Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel is also known as XRP6258, a semisynthetic taxane from a single diastereoisomer of 10-deacetyl baccatin III derived from the needles of various Taxus species. A stability-indicating high performance liquid chromatographic technique was developed for the determination of Cabazitaxel in bulk and pharmaceutical formulations. Chromatographic separation was performed on Shimadzu Model CBM-20A/20 Alite, using Zorbax SB-C18 column (150 mm×4.6 mm i.d., 3.5 μm particle size) with a mixture of 0.1% ortho phosphoric acid and methanol (20:80, v/v) as mobile phase with a flow rate of 1.0 ml/ min. Cabazitaxel was subjected to stress conditions (acidic, alkaline, oxidation photolytic and thermal degradations and the method were validated as per ICH guidelines.